← Back to all signals
BSX · Q2 2026

BOSTON SCIENTIFIC CORP

Reported 2026-07-29
BEAT
51EarnIQ signal
↗

Confidence rising

Mild quarter-over-quarter shift

Solid execution with strong operational revenue growth and an EPS beat positions BSX favorably for long-term category leadership.

  • ✓Guidance was maintained, with high specificity.
  • ✓Management tone registered as confident (85/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Headline confirmed

Management confidence reinforces the reported beat.

EPS: reported vs expected+2.9%$0.86 vs $0.84
Revenue: reported vs expected+0.5%$5.4B vs $5.4B
Guidance specificityHighMaintained
Market expectations supplied by Finnhub · Reported vs consensus estimate

Our team delivered a solid quarter while continuing to navigate a dynamic environment, anchored by our category leadership strategy.

Premium intelligence

The evidence behind the signal

Full report
Management language

Why confidence moved

“Our team delivered a solid quarter while continuing to navigate a dynamic environment”
“We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities”
“we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy”
Guidance specificity
90/100

High specificity

The company estimates full year 2026 net sales growth of approximately 5.5 to 6.5 percent on a reported basis and adjusted EPS of $3.28 to $3.32.

Pressure point
!

Economic conditions and foreign currency

0 potential deflections detected in management communication.

Narrative break

What changed

Investment in MiRus LLC for biomaterials and the SIEGEL TAVR system strengthens cardiovascular and orthopedic positioning.

Q&A evidence

Management responses

No material Q&A deflections were detected.

Key positives
  • Second quarter net sales grew 7.5 percent reported and 7.0 percent organically
  • Cardiovascular segment delivered strong revenue growth of 8.3 percent reported
  • Adjusted EPS of $0.86 exceeded guidance range of $0.82 to $0.84
Key risks
  • Economic conditions and foreign currency fluctuations
  • Regulatory conditions and shifting trade/tariff policies
  • Variations in outcomes of ongoing and future clinical trials
Topic velocity

Language versus prior quarter

M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition

What drove the EarnIQ score

Tone+20
Eps Beat+0
Guidance+15
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0